Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer

Cancer Research

Volumn 56, Issue 17, 1996, Pages 3961-3966

  Cascorbi, Ingolf ^a   Brockmöller, Jürgen ^a   Mrozikiewicz, Przemyslaw M ^a   Bauer, Steffen ^a   Loddenkemper, Robert ^b   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Lungenklinik Heckeshorn ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ACETYLATION; ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0029837310     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Kawajin, K , Nakachi, K , Imai, K , Watanabe, J., and Hayashi, S. The CYP1A1 gene and cancer susceptibility. Crit. Rev. Oncol Hematol., 14: 77-87, 1993.
2. Drakoulis, N , Cascorbi, I., Brockmöller, J , Gross, C. R , and Roots, I Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer, exon-7 mutauon (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin. Invest., 72: 240-248, 1994.
3. Nazar-Stewart, V., Motulsky, A. G , Eaton, D L., White, E., Hornung, S K , Leng, Z T , Stapleton, P., and Weiss, N. S. The glutathione S-transferase μ polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res , 53: 2313-2318, 1993.
4. Ayesh, R , Idle, J. R., Ritchie, J C., Crothers, M. J , and Hetzel, M. R Metabolic oxidation phenotypes as markers for susceptibility to lung cancer Nature (Lond). 312: 169-170, 1984
5. Roots, I., Drakoulis, N., Ploch, M., Hememeyer, G., Loddenkemper, R., Minks, T., Nitz, M., Otte, H., and Koch, M. Debrisoquine hydroxylation phenotype, acetylation phenotypes, and ABO blood groups as genetic host factors of lung cancer risk. Klin. Wochenschr., 66 (Suppl XI): 87-97, 1988.
6. Brockmöller, J., Kerb, R , Drakoulis, N., Nilz, M., and Roots, I Genotype and phenotype of glutathione S-transferase class μ isoenzymes μ and ψ in lung cancer patients and controls. Cancer Res , 53: 1004-1011, 1993.
7. Roots, I , Drakoulis, N., and Brockmoller, J. Polymorphic enzjmes and cancer risk: concepts, methodology and data review. In: W Kalow (ed.), Pharmacogenetics of Drug Metabolism, pp. 815-841. New York, Pergamon Press, 1992.
8. Daly, A K., Cholerton, S., Armstrong, M., and Idle, J. R. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility Environ Health Perspect., 102: 55-61, 1994.
9. Risch, A , Wallace, D M A., Bathers, S., and Sim, E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet., 4: 231-236, 1995.
10. Brockmoller, J , Cascorbi, I , Kerb, R., and Roots, I Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res., 56: 3915-3925, 1996.
11. Philip, P A., Fitzgerald, D. L., Cartwright, R A., Peake, M. D , and Rogers, H. J. Polymorphic N-acetylation capacity in lung cancer. Carcinogenesis (Lond.), 9: 491-493, 1988.
12. Roots, I., Drakoulis, N., Brockmöller, J., Jamcke, I , Cuprunov, M., and Ritter, J. Hydroxylation and acetylation phenotypes as genetic risk factors in certain malignancies. In R. Kato, R. W. Estabrook, and M. N. Cayen (eds.). Xenobiotic Metabolism and Disposition. pp 499-506. London, Taylor & Francis, 1989.
13. Cascorbi, I., Drakoulis, N., Brockmoller, J., Maurer, A., Sperling, K., and Roots, I. Arylamine N-aceryltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet., 57: 581-592, 1995.
14. Hein, D. W., Ferguson, R. J., Doll, M. A , Rustan, T. D., and Gray, K Molecular genetics of human polymorphic N-acetyltransferase enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2allozymes. Hum Mol. Genet., 3: 729-734, 1994.
15. Hickman, D., Palamanda, J. R., Unadkat, J. D , and Sim, E Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli. Biochem. Pharmacol , 50: 697-703, 1995.
16. Lang, N. P and Kadlubar, F. F. Aromatic and heterocyclic amine metabolism and phenotyping in humans Prog. Clin. Biol. Res , 372: 33-47, 1991.
17. Hein, D. W., Doll, M. A., Rustan, T. D., Gray, K., Feng, Y., Ferguson, R J , and Grant, D M. Metabolic activation and deactivation of arylamine carcinogens by recombinam human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis (Lond.), 14: 1633-1638, 1993.
18. Wild, D., Feser, W , Michel, S., Lord, H L., and Josephy, P D. Metabolic activation of heterocyclic aromatic amines catalyzed by human arylamine N-acetyltransferase isozymes (NAT1 and NAT2) expressed in Salmonella typhimurium Carcinogenesis (Lond), 16: 643-648, 1995.
19. Grant, D M , Tang, B. K., and Kalow, W. A simple test for acetylator phenotype using caffeine Br. J. Clin. Pharmacol., 17: 459-464, 1984.
20. Sambrook, J., Fritsch, E F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed. 2, pp 9 17-9 19. New York. Cold Spring Harbor Laboratory, 1989
21. Blum, M., Grant, D. M., McBride, W , Heim, M , and Meyer, U. A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol., 9: 193-203, 1990
22. Degushi, T , Mashimo, M., and Suzuki, T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem., 265 12757-12760, 1990
23. Vatsis, K P., Martell, K J , and Weber, W. W. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl Acad Sci. USA. 88. 6333-6337, 1991.
24. Bell, D. A., Taylor, J A , Butler, M A., Stephens, E A., Wiest, J., Brubaker, L. H., Kadlubar, F. F , and Lucier, G W Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans Carcinogenesis (Lond). 14: 1689-1692, 1993.
25. Vatsis, K P., Weber, W. W , Bell, D A., Dupret, J. M., Evans., D. A P., Grant, D. M., Hem, D W , Lin, H. J., Meyer, U. A , Relling, M. V., Sim, E , Suzuki, T., and Yamazoe, Y. Nomenclature for N-acetyltransferases. Pharmacogenetics, 5 1-17, 1995
26. Mrozikiewicz, P. M , Cascorbi, I., Brockmoller, J , and Roots, I Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase (NAT2) gene in the Polish population. Clin. Pharmacol & Ther., 59: 376-382, 1996.
27. Grant, D M., Blum, M , Demierre, A , and Meyer, U A. Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res , 17: 3978, 1989.
28. Dixon W J. BMDP Statistical Software Manual. Berkeley, CA: University of California Press, 1992.
29. Mrozikiewicz, P. M., Drakoulis, N , and Roots, I Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus Clin Pharmacol. & Ther., 50: 626-634, 1994.
30. Burgess, E. J , and Trafford, J. A. Acetylator phenotype in patients with lung carcinoma a negative report. Eur. J Respir Dis . 67: 17-19, 1985
31. Martinez, C , Agundez, J. A G , Olivera, M , Martin, R , Ladero, J M , and Benitez, J Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics, 5: 207-214, 1995
32. Henning, S., Cascorbi, I., Jahnke, V., and Roots, I. The rapid arylamine N-acetyltransferase (NAT2) genotype: a hereditary susceptibility factor for laryngeal cancer. In. J. A. Werner, B. M. Lippert, and H. H. Rudert (eds.). International Symposium on Advances in Head and Neck Cancer, Kiel, Germany, 18-20 January 1996. Excerpta Medica International Congress Series 1114. Amsterdam: Elsevier Science, in press, 1996
33. Cascorbi, I., Brockmöller, J., Bauer, S., Reum, T., and Roots, I. NAT2*12A (803A→G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics, 6: 257-260, 1996.
34. Lower, G. M , Nilsson, T., Nelson, C. E., Wolf, H., Gamsky, T. E., and Bryan, G. T. N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspeci., 29: 71-79, 1979.
35. Evans, D. A. P., Eze, L. C., and Whibley, E. J. The association of the slow acetylator phenotype with bladder cancer. J. Med. Genet., 20: 330-333, 1983.
36. Kloth, M. T., Gee, R. L., Messing, E. M., and Swaminathan, S. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis (Lond), 15: 2781-2787, 1994.
37. Lang, N. P., Butler, M A., Massengill, J., Lawson, M., Stotts, R. C., Hauer-Jensen, M., and Kadlubar, F F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to foodborne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol., Biomarkers & Prev., 3: 675-682, 1994.
38. Ilett, K. F., Ingram D. M., Carpenter, D. S., Teitel, C. H , Lang, N. P., Kadlubar, F F., and Minchin, R. F Expression of monomorphic and polymorphic N-acetyltransferases m human colon. Biochem Pharmacol., 47: 914-917, 1994.
39. Rodriguez, J. W., Kirlin, W. G , Ferguson, R. J., Doll, M. A., Gray, K., Rustan, T. D , Lee, M. E., Kemp, K., Urso, P., and Hem, D. W. Human acetylaeor genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol Arch. Toxicol., 67: 445-452, 1993.
40. Bell, D. A., Badawi, A. F., Lang N. P., Ilett, K. F , Kadlubar, F. F., and Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal, association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue Cancer Res , 55: 5226-5229, 1995.
41. Eaton, D L., Gallagher, E. P., Bammler, T. K., and Kunze, K. L. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics, 5: 259-274, 1995.
42. Lin, H. J , Han, C Y., Lin, B. K., and Hardy, S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics, 4: 125-134, 1994.